FDA Approves Lantheus' PYLARIFY TruVu for Enhanced Prostate Cancer Imaging
核心洞察
The FDA has approved PYLARIFY TruVu (搜索) (piflufolastat F 18 (搜索)), a new formulation of Lantheus' market-leading PSMA (搜索) PET imaging agent for prostate cancer diagnosis.
The enhanced formulation is designed to improve manufacturing efficiency and enable larger batch sizes, potentially increasing patient access to PSMA (搜索) PET imaging.
PYLARIFY TruVu (搜索) maintains the same diagnostic performance as the original PYLARIFY, which has been used in over 760,000 prostate cancer scans since 2021.
The U.S. Food and Drug Administration has approved PYLARIFY TruVu (搜索) (piflufolastat F 18 (搜索)) injection, a new formulation of Lantheus Holdings (搜索)' widely-used PSMA (搜索) PET imaging agent for prostate cancer. The approval represents a significant advancement in radiopharmaceutical manufacturing that could enhance patient access to critical diagnostic imaging.
PYLARIFY TruVu (搜索) is indicated for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA (搜索)) positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA) levels.
Enhanced Manufacturing and Supply Chain Benefits
The new formulation addresses a key clinical need identified by healthcare providers: greater access to PSMA (搜索) PET imaging. PYLARIFY TruVu (搜索) is designed to enhance product stability at higher radioactive concentrations, supporting more efficient manufacturing and distribution processes.
"The availability of PYLARIFY TruVu (搜索) addresses a key need identified by clinicians – greater access to our market-leading formulation," said Mary Anne Heino, Executive Chairperson and CEO of Lantheus.
The enhanced stability profile is expected to increase batch sizes, enabling manufacturing sites with high-energy cyclotrons to reach more patients and serve broader geographic markets. These improvements have the potential to enhance supply flexibility and improve operating leverage for the network of PET manufacturing facilities (PMFs) that will produce and distribute the product.
Proven Clinical Performance
PYLARIFY TruVu (搜索) was approved through the FDA's 505(b)(2) regulatory pathway, leveraging previously submitted data from two pivotal PYLARIFY studies: OSPREY and CONDOR. The new formulation maintains the same diagnostic properties and is expected to offer similar safety and effectiveness as the original PYLARIFY.
The OSPREY phase 2/3 clinical trial evaluated 385 patients, with 252 men with high-risk prostate cancer having evaluable histopathology for determining diagnostic performance in identifying pelvic nodal metastases. The study demonstrated median sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 38% (26, 51), 96% (94, 99), 77% (62, 92), and 83% (78, 88), respectively.
Compared to standard imaging, PYLARIFY PET/CT delivered significantly higher specificity (97.9% vs 65.1%), nearly three times the PPV (86.7% vs 28.3%), and similar sensitivity (40.3% vs 42.6%).
The CONDOR phase 3 trial included 208 patients with suspected recurrent or metastatic prostate cancer with negative or equivocal results using standard imaging. The study achieved its primary endpoint of correct localization rate (CLR) of 85%-87% across all three readers (lower bound of 95% CI: 78%-80%).
Safety Profile and Market Impact
Safety evaluation in 593 clinical patients showed PYLARIFY was generally well tolerated. The most common adverse reactions, reported in ≤2% of patients, were headache, dysgeusia, and fatigue. One delayed hypersensitivity reaction (0.2%) was reported in a patient with a history of allergic reactions.
Since FDA approval in May 2021, more than 760,000 people with prostate cancer have received PSMA (搜索) PET scans with PYLARIFY across 48 states, Puerto Rico, and Washington, D.C., establishing it as the number one utilized PSMA PET imaging agent in the United States.
Addressing Growing Clinical Need
The approval comes at a critical time as prostate cancer incidence continues to rise. Prostate cancer is the second most common form of cancer affecting men in the U.S., with an estimated 1 in 8 men diagnosed in their lifetime. The incidence rate has been increasing since 2014 at a rate of 3% per year overall, with estimates suggesting nearly 334,000 new cases and more than 36,000 deaths in 2026.
"With prostate cancer incidence expected to rise in the years ahead, it's encouraging to see companies like Lantheus putting patients first and introducing innovations that help ensure timely, precise imaging while keeping pace with growing demand," said Gina B. Carithers, President and CEO of the Prostate Cancer Foundation.
Commercial Launch Timeline
PYLARIFY TruVu (搜索) is expected to be commercially available in the fourth quarter of 2026, with introduction on a rolling geographic basis. This phased approach is designed to allow customers to transition from PYLARIFY to the new formulation with minimal disruption to patient care.
The enhanced formulation represents Lantheus' continued commitment to advancing diagnostic innovation while strengthening supply chain reliability for healthcare providers treating prostate cancer patients.